AbbVie Stock: Buy, Sell, or Hold in October?

AbbVie, a pharmaceutical giant with 53 consecutive years of dividend increases, remains a stable long-term investment despite losing U.S. patent exclusivity for its blockbuster drug Humira in 2023. The company has offset this decline through new immunology drugs (Skyrizi and Rinvoq) and strategic acquisitions including Allergan (Botox). Analysts project 9% revenue CAGR and 21% adjusted EPS CAGR from 2025-2028. At $264 per share with a 2.6% forward yield and 16x forward P/E, the stock is reasonably valued for buy-and-hold investors.

09/30/2026, 12:30 PM • The Motley Fool

Novo Nordisk Gives Uninspiring Outlook

Novo Nordisk provided disappointing guidance to investors, forecasting a considerable slowdown in revenue growth. The company faces challenges including the patent cliff for its blockbuster drug Ozempic, which management acknowledged as a significant concern.

09/29/2026, 11:26 PM • The Motley Fool

Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks.

Federal Reserve Chair Kevin Warsh's hawkish stance signals sustained higher interest rates to combat inflation. While this increases competition for dividend stocks from Treasury bonds, big pharma dividend stocks like Pfizer, AbbVie, and Bristol Myers Squibb should remain resilient due to strong fundamentals and manageable debt service costs. Historical data shows pharma-specific business factors matter more than interest rates for stock performance.

09/27/2026, 5:30 AM • The Motley Fool

Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - SNS Insider

The global Enzyme Replacement Therapy (ERT) market is projected to grow from USD 12.24 billion in 2025 to USD 27.90 billion by 2035, with a CAGR of 8.59%. Growth is driven by early identification of rare lysosomal storage disorders, increased newborn screening, orphan drug incentives, and expanding healthcare access. North America leads with 38.76% market share, while Asia-Pacific shows the fastest growth at 9.43% CAGR. Imiglucerase dominates products, and Gaucher disease represents the largest therapeutic condition.

09/25/2026, 8:30 AM • GlobeNewswire

Reuters Momentum AI Austin Day 1: A New Way to Measure Whether AI Is Actually Paying Off

Enterprise AI is shifting from experimentation to demonstrating measurable ROI. Companies like FedEx ($3B in cost reductions), Mars (20% top-line growth), and Indeed (70% of matches from AI) are scaling AI beyond pilots, but success requires organizational redesign, clear ownership, and human oversight. Leaders warn that AI can amplify existing organizational weaknesses and autonomous agents need defined spending limits and accountability measures.

09/24/2026, 8:30 PM • GlobeNewswire

ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering

ADARx Pharmaceuticals, a late-stage clinical biotechnology company developing siRNA therapeutics, priced its IPO at $17 per share for 26.25 million shares, generating approximately $446.3 million in gross proceeds. The company will begin trading on Nasdaq under ticker 'ADRX' on September 25, 2026. AbbVie has agreed to purchase shares in a concurrent private placement for approximately $100 million, resulting in a 4.9% stake in ADARx.

09/24/2026, 7:33 PM • GlobeNewswire

Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight

The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding biosimilar availability. North America leads with 44% market share, while Asia-Pacific is the fastest-growing region. Key players include AbbVie, Johnson & Johnson, Pfizer, Novartis, and Roche.

09/24/2026, 1:00 PM • GlobeNewswire

Skin Boosters Market Expands as Regenerative PDRN Formulations Broaden Minimally Invasive Aesthetics

The global skin boosters market is experiencing significant growth driven by increasing consumer demand for minimally invasive aesthetic procedures. The market, valued at $1.40 billion in 2025, is projected to reach $4.30 billion by 2035, with a CAGR of 11.89%. Growth is fueled by expanding medspa access, regenerative ingredients like PDRN, and rising awareness of hyaluronic acid treatments. The U.S. market is expected to grow from $0.36 billion to $1.08 billion, while Asia Pacific shows the highest growth potential at 12.70% CAGR.

09/23/2026, 8:30 PM • GlobeNewswire

Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH

The Invesco Nasdaq Biotechnology ETF (IBBQ) offers lower costs (0.19% expense ratio) and higher 1-year returns (44.6%), making it suitable for growth-focused investors willing to accept volatility. The iShares U.S. Healthcare ETF (IYH) provides broader diversification across 100 healthcare holdings with higher dividend yield (1.1%) and lower volatility, appealing to conservative investors seeking stability and income.

09/22/2026, 10:04 PM • The Motley Fool

AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?

The article compares two pharmaceutical dividend stocks: AbbVie and Pfizer. AbbVie is a Dividend King with 50+ consecutive years of dividend increases, offering a 2.6% yield and $18 billion in free cash flow, with strong growth from immunology products like Rinvoq and Skyrizi. Pfizer is in recovery mode post-pandemic, offering a higher 6.2% dividend yield but with less consistent growth. The author recommends AbbVie as the better dividend buy due to its proven ability to grow dividends sustainably and demonstrated business resilience after losing Humira exclusivity.

09/22/2026, 6:05 AM • The Motley Fool

Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight

The psoriatic arthritis market is expected to expand significantly through 2036 driven by emerging late-stage therapies from major pharmaceutical companies. Key drugs in development include tildrakizumab (Sun Pharma), sonelokimab (MoonLake), icotrokinra (Johnson & Johnson), zasocitinib (Takeda), izokibep (Affibody Medical), and vunakizumab (Suzhou Suncadia). These novel biologic and oral small-molecule therapies aim to address unmet needs among patients with inadequate responses to existing treatments.

09/21/2026, 1:00 PM • GlobeNewswire

Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder

Bristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers despite strong Q2 performance with $12.9B revenue and 153% EPS growth. The company's growth portfolio of newer drugs now accounts for nearly 60% of revenue and grew 15% year-over-year, offsetting concerns about patent expirations on legacy drugs. With a 3.95% dividend yield, $5B buyback program, and potential acquisition interest from AstraZeneca, analysts see significant upside potential as the market has underpriced the stock relative to its pipeline execution.

09/20/2026, 8:30 AM • The Motley Fool

Body Contouring Devices Market Expands as Non-Invasive Technology Reaches Untapped Male Demographic

The global body contouring devices market is expected to grow from $2.41 billion in 2025 to $8.82 billion by 2035, with a CAGR of 13.84%. Non-invasive treatments dominate with 78.4% market share, driven by rising obesity rates and increasing demand for non-surgical aesthetic procedures. The U.S. market alone is projected to reach $2.74 billion by 2035. Key growth drivers include expanding male demographics, multi-modal technology platforms, and rising social media influence on aesthetic awareness.

09/18/2026, 8:30 PM • GlobeNewswire

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie and Bristol Myers Squibb are compared as pharmaceutical investment options for 2026. AbbVie is recommended as the better buy due to its successful immunology franchise with Skyrizi and Rinvoq driving growth, diversification into aesthetics and neuroscience, and having navigated its patent cliff challenges. Bristol Myers Squibb, while cheaper on valuation metrics and maintaining strong profit margins, faces revenue stagnation, legal uncertainties from a Celgene acquisition lawsuit, and is still working through its own portfolio transition challenges.

09/18/2026, 9:15 AM • The Motley Fool

Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape

The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.

09/17/2026, 6:49 AM • GlobeNewswire